beta-lapachone has been researched along with as 1411 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Fan, X; Ji, J; Li, L; Xu, W; Zhou, K | 1 |
1 other study(ies) available for beta-lapachone and as 1411
| Article | Year |
|---|---|
A novel multifunctional nanoparticles formed by molecular recognition between AS1411 aptamer and redox-responsive paclitaxel-nucleoside analogue prodrug for combination treatment of β-lapachone and paclitaxel.
Topics: Aptamers, Nucleotide; Cell Line, Tumor; Multifunctional Nanoparticles; Nanoparticles; Naphthoquinones; Nucleosides; Oligodeoxyribonucleotides; Oxidation-Reduction; Paclitaxel; Prodrugs | 2022 |